← Human Trials & Peer-Reviewed Studies
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
Plain-language guide to PMID 37000452 (2023): open-label randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 37000452
- Journal
- JAMA network open
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Werlenius K et al. (17 authors)
- DOI
- 10.1001/jamanetworkopen.2023.4149
- Registered trial
- NCT02678975
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
One of the proposed indications is for the treatment of glioblastoma.
ClinicalTrials.gov Identifier: NCT02678975; EUDRACT Identifier: 2016-000167-16.
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
Patients were recruited at 7 study sites in Sweden and 2 sites in Norway between January 2017 and November 2020.
Eligible patients were 18 years or older, had a first recurrence of glioblastoma, and indication for treatment with alkylating chemotherapy.
How the Study Was Run
In design terms this was a randomized, open-label, multicenter and parallel-group study.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Being open-label, the Copper (Supplement) study did not mask who received what.
Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.
The Copper (Supplement) group and the comparison group ran side by side rather than switching.
This was a multicenter, open-label, randomized phase II/III clinical trial with parallel group design.
The date of final follow-up was January 15, 2021.
Data analysis was performed from February to September 2022.
What Was Measured
Topics PubMed links to this paper include Glioblastoma, Copper, Disulfiram, Quality of Life and Antineoplastic Combined Chemotherapy Protocols.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Copper (Supplement).
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (JAMA network open), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.